Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ascentage Pharma (NASDAQ: AAPG) said its management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Wednesday, January 14, 2026 at 2:15 p.m. PT. Ascentage Pharma is described as a global, commercial-stage, integrated biopharmaceutical company focused on discovery, development and commercialization of novel cancer therapies.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AAPG declined 3.15%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AAPG gained 6.66% while close biotech peers were mixed (e.g., MIRM +3.98%, ZLAB -0.82%, ARWR -4.98%), suggesting a company-specific move rather than a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Phase II follow-up data | Positive | -4.0% | Four-year Phase II data for olverembatinib in TKI-resistant CML-CP. |
| Dec 08 | Clinical data update | Positive | -4.0% | Updated ASH 2025 second-line CML-CP data for olverembatinib. |
| Dec 08 | Phase III dataset | Positive | -4.0% | First Phase III POLARIS-1 dataset in newly diagnosed Ph+ ALL. |
| Dec 07 | Phase Ib/II results | Positive | -4.8% | Phase Ib/II lisaftoclax data in venetoclax-exposed myeloid malignancies. |
| Dec 04 | Regulatory trial clearance | Positive | +1.1% | FDA/EMA clearance of global registrational Phase III POLARIS-1 study. |
Recent positive clinical and trial updates often coincided with negative next-day moves, except for one regulatory clearance that aligned with a modest gain.
Over the last weeks, Ascentage Pharma has focused on clinical data for olverembatinib and lisaftoclax and the global Phase III POLARIS-1 program. Multiple ASH 2025 presentations showed differentiated efficacy and safety in CML and Ph+ ALL, plus encouraging data in myeloid malignancies. Despite broadly positive clinical signals, several of these updates were followed by share price declines of about -4%, indicating a tendency for good news to meet selling pressure. The J.P. Morgan conference appearance follows this dense data period.
Market Pulse Summary
This announcement highlights Ascentage Pharma’s planned presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 2:15 p.m. PT, offering another venue to showcase its recent ASH 2025 clinical data and Phase III POLARIS-1 progress. Investors reviewing this update may contextualize it with the company’s recent sequence of positive hematology and oncology readouts and global trial clearances, while monitoring future clinical milestones and regulatory disclosures for more direct fundamental impact.
AI-generated analysis. Not financial advice.
ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for Wednesday, January 14, 2026, at 2:15 p.m. PT.
About Ascentage Pharma Group International
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key apoptotic pathway proteins, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.
Ascentage Pharma's first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the US FDA, the EMA of the EU, and China CDE.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Stella Yang
Ascentage Pharma
Stella.Yang@ascentage.com
+1 (301) 792-6286
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012
FAQ
When will Ascentage Pharma (AAPG) present at the J.P. Morgan Healthcare Conference?
Where is the 44th Annual J.P. Morgan Healthcare Conference presentation by AAPG taking place?
What will Ascentage Pharma (AAPG) likely cover in its January 14, 2026 presentation?
How can investors access Ascentage Pharma (AAPG) presentation at the conference?
What is Ascentage Pharma’s business focus noted in the January 14, 2026 announcement?
